SBIR Phase I: Development of a 32 Site Ion Channel Measurement Consumable

SBIR 第一阶段：开发 32 位离子通道测量耗材

• 批准号: 1214810
• 负责人: Jason Poulos
• 金额: $ 15万
• 依托单位: Librede Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-07-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1214810&HistoricalAwards=false
• 关键词: SBIR; Phase; Development; 32; Site

This Small Business Innovation Research Phase I project is aimed at developing improved technology for drug discovery and safety screening of ion channels. Ion channels are present in every cell and play key roles in a wide range of physiological processes including the cardiac cycle and neural activity. Librede Inc. is developing an ion channel screening platform based on artificial cell membrane technology that has the potential for decreased instrumentation and running costs with higher throughput and minimal training. In the work proposed here, Librede will design and fabricate a consumable prototype ion channel array plate with 32 measurement sites and measure an ion channel across the whole plate simultaneously. At the completion of this Phase I work we will have an SBS standard consumable array plate ready for integration into an automated platform with solution perfusion to be developed in Phase II.The broader/commercial impacts of this research are to decrease the cost and increase the throughput of ion channel screening. These are well-recognized pain points felt by pharmaceutical and academic researchers. This problem is shared for screening of all drug candidates, since all drugs must be screened against cardiac ion channels for issues of safety. Librede?s fundamentally different approach to ion channel screening will streamline the screening process, reducing its cost and time, resulting in better/safer drugs reaching the market sooner. Our platform gives us a competitive advantage in cost, throughput, and ease of use when compared to the state of the art.

该小企业创新研究第一阶段项目旨在开发用于药物发现和离子通道安全筛选的改进技术。离子通道存在于每个细胞中，并在包括心动周期和神经活动在内的广泛生理过程中发挥关键作用。 Librede Inc. 正在开发一种基于人造细胞膜技术的离子通道筛选平台，该平台有可能通过更高的通量和最少的培训来降低仪器和运行成本。在此提出的工作中，Librede 将设计和制造具有 32 个测量位点的消耗品原型离子通道阵列板，并同时测量整个板的离子通道。第一阶段工作完成后，我们将拥有一个 SBS 标准耗材阵列板，可集成到第二阶段开发的具有溶液灌注的自动化平台中。这项研究的更广泛/商业影响是降低成本并提高离子通道筛选的通量。这些是制药和学术研究人员公认的痛点。这个问题是筛选所有候选药物所共有的，因为出于安全问题，所有药物都必须针对心脏离子通道进行筛选。 Librede 的根本不同的离子通道筛选方法将简化筛选过程，降低成本和时间，从而使更好/更安全的药物更快地进入市场。与最先进的技术相比，我们的平台为我们提供了成本、吞吐量和易用性方面的竞争优势。